Study procedures
tumor
TUMOR
Patients were assigned to at least one 90‐min outpatient AutEMdev exposure procedure. Healthy volunteers were assigned to one exposure procedure only. Patients were invited to repeat procedures every 2–4 weeks if the patient or physician perceived quality of life improvement or objective tumor response. Patients could continue until withdrawal of consent or deterioration in quality of life (10% decrease from baseline in EORTC QLQ–C30 global health status). Patients could receive AutEMdev as a monotherapy or in combination with any conventional treatment approved by the Brazilian health regulatory agency, at any time. All patients were allowed to maintain any supportive care.Exposure procedures were conducted with continuous assistance from healthcare professionals. Participants were placed in the supine position wearing a comfortable outfit in a quiet, low‐light ambiance to allow hemodynamic parameters to stabilize. Pressure cuffs were positioned, and the spoon‐shaped AutEMdev antenna was placed over the patient's tongue (Figure Hemodynamic variability alterations during EMF exposure with the AutEMdev. (A) Participant undergoing the procedure showing the AutEMdev and intrabuccal spoon‐shaped antenna. (B,C) Hemodynamic variability without and during exposure to amplitude‐modulated EMFs. (D) Power law distribution and (E) Linearized function for the number of hemodynamic signals of interest identified in 10 specific amplitude‐modulation frequency bands, following division of the time series into 100‐s intervals (data from study part 2). Abbreviations: AutEMdev indicates Autem electromagnetic device; EMF, electromagnetic field; NResp, number of responses (i.e., hemodynamic signals of interest).